Zolgensma, an FDA-approved treatment for patients < 2 years of age with spinal muscular atrophy, utilizes adenovirus vector 9 (AA9) for the delivery of the survival motor neuron 1 (SMN1) gene to motor neurons in the central nervous system for the production of the SMN protein [57]. The gene discussed is SMN1; the disease is spinal muscular atrophy.